 |
|
 |
- December 1, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Glycaemic Efficacy of TZDs"Prof. Don Chisholm (biography)
English - 2007-11-10 - 22 minutes
|
 | (23 slides) |
Summary :
The pathophysiology of type 2 diabetes involves both insulin resistance and β-cell dysfunction.
As the United Kingdom Prospective Diabetes Study showed, in all arms of the study there was a progressive loss of glycaemic control, and a separate analysis showed there was a progressive failure of β-cell function after the first year.
HOMA estimates of ß-cell function and insulin resistance showed significant mean increases in ß-cell function and reductions in insulin resistance among rosiglitazone-treated patients, in a study published by Lebovitz et al. in 2001 (1). Two subsequent major studies, the DREAM (2) and ADOPT (3) studies, looked at the prevention of progression to type 2 diabetes with rosiglitazone in prediabetic subjects, and a comparison of the glycaemic efficacy and durability of rosiglitazone compared to sulfonylurea or metformin.
Prof. Chisholm summarises from the glycaemic point of view the results of these large randomised trials.
Copyright © 2008 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Data on HOMA estimates of ß-cell function and insulin resistance in rosiglitazone-treated patients with type 2 diabetes (Lebovitz et al. JCEM 2001)
- Reduction in the incidence of type 2 diabetes with rosiglitazone in prediabetic subjects (DREAM trial)
- Glycaemic efficacy and durability data for rosiglitazone compared to sulfonylurea or metformin (ADOPT trial)
Bibliographic references :
1. Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 1 280-288.
2. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial The Lancet Volume 368, Issue 9541, 23 September 2006-29 September 2006, Pages 1096-1105.
3. Steven E. Kahn, M.B., Ch.B., Steven M. Haffner, M.D., Mark A. Heise, Ph.D., William H. Herman, M.D., M.P.H., Rury R. Holman, F.R.C.P., Nigel P. Jones, M.A., Barbara G. Kravitz, M.S., John M. Lachin, Sc.D., M. Colleen O'Neill, B.Sc., Bernard Zinman, M.D., F.R.C.P.C., Giancarlo Viberti, M.D., F.R.C.P., for the ADOPT Study GroupGlycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy NEJM 2006 Volume 355:2427-2443.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
